FIT Biotech as an investment

FIT Biotech offers investors an unprecedented opportunity to participate in the international commercialization of drug candidates based on Finnish biotechnology aiming at a dramatic improvement of human health and affordability. We also offer a huge market potential – our target markets are in the billions of euros (antibodies against cancer approximately 100 billion euros and HIV about 20 billion euros). While drug development is an inherently long term process, there should be multiple milestones met along the way and early stage licensing agreements are current norm.